Latest Stories
2 Reasons to Like LOB (and 1 Not So Much)
Live Oak Bancshares has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.5%. The stock now trades at $35.23, marking a 18.2% gain. This run-up might have investors contemplating their next move.
Dave & Buster's (PLAY): Buy, Sell, or Hold Post Q3 Earnings?
Dave & Buster’s stock price has taken a beating over the past six months, shedding 45.7% of its value and falling to $16.34 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
3 Reasons to Sell ACEL and 1 Stock to Buy Instead
Since June 2025, Accel Entertainment has been in a holding pattern, posting a small loss of 0.6% while floating around $11.70. The stock also fell short of the S&P 500’s 11.7% gain during that period.
2 Reasons to Avoid COLL and 1 Stock to Buy Instead
Collegium Pharmaceutical has been on fire lately. In the past six months alone, the company’s stock price has rocketed 68.7%, setting a new 52-week high of $49.89 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
2 Reasons to Watch FBP and 1 to Stay Cautious
First BanCorp has been treading water for the past six months, recording a small return of 1.8% while holding steady at $21.20. The stock also fell short of the S&P 500’s 11.7% gain during that period.
3 Reasons We’re Fans of Sea (SE)
Shareholders of Sea would probably like to forget the past six months even happened. The stock dropped 20.3% and now trades at $127.54. This might have investors contemplating their next move.
3 Reasons to Sell SMPL and 1 Stock to Buy Instead
Simply Good Foods has gotten torched over the last six months - since June 2025, its stock price has dropped 36.7% to $20 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
2 Reasons to Like CL and 1 to Stay Skeptical
Over the past six months, Colgate-Palmolive’s shares (currently trading at $79.74) have posted a disappointing 12.3% loss, well below the S&P 500’s 11.7% gain. This might have investors contemplating their next move.
Reflecting On Pharmaceuticals Stocks’ Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ)
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.
Q3 Earnings Outperformers: Campbell's (NASDAQ:CPB) And The Rest Of The Shelf-Stable Food Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Campbell's (NASDAQ:CPB) and its peers.